Candel Therapeutics, Inc. (CADL) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
CADL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CADL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | 100.0% | -27777.6% | -15035.2% |
| 2021 | -11575.2% | -20580.8% | -28899.2% |
Download Data
Export CADL earnings history in CSV or JSON format
Free sign-in required to download data
Candel Therapeutics, Inc. (CADL) Earnings Overview
As of May 8, 2026, Candel Therapeutics, Inc. (CADL) reported trailing twelve-month net income of -$9M, reflecting +58.6% year-over-year growth. The company earned $-0.16 per diluted share over the past four quarters.
Looking at the long-term picture, CADL's historical earnings data spans multiple years. The company achieved its highest annual net income of $0 in fiscal 2025, representing a new all-time high.
Candel Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), IMCR (-$19M net income, -8.9% margin), IOVA (-$354M net income, -148.4% margin), CADL has comparable earnings metrics. Compare CADL vs IMVT →
CADL Earnings vs Peers
Earnings metrics vs comparable public companies
CADL Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | +100.0% | -$48M | $-0.72 | - | - |
| 2024 | -$55M | -45.4% | -$33M | $-1.74 | - | - |
| 2023 | -$38M | -101.9% | -$38M | $-1.31 | - | - |
| 2022 | -$19M | +48.0% | -$35M | $-0.10 | -15035.2% | -27777.6% |
| 2021 | -$36M | -104.3% | -$26M | $-1.26 | -28899.2% | -20580.8% |
| 2020 | -$18M | -114.6% | -$14M | $-1.18 | -14144.0% | -11048.0% |
| 2019 | -$8M | - | -$9M | $-0.43 | -6592.0% | -7229.6% |
See CADL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CADL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CADL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCADL — Frequently Asked Questions
Quick answers to the most common questions about buying CADL stock.
Is CADL growing earnings?
CADL EPS is $-0.16, with earnings growth accelerating to +58.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are CADL's profit margins?
Candel Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CADL's earnings?
CADL earnings data spans 2019-2025. The accelerating earnings trend is +58.6% YoY. Historical data enables comparison across business cycles.